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ABSTRACT 
Background & aims:  The literature regarding the potential health benefits of chocolate 
consumption are unclear and the epidemiological credibility has not been systematically scrutinized, 
while the strength of the evidence is undetermined. We therefore aimed to map and grade the 
diverse health outcomes associated with chocolate consumption using an umbrella review of 
systematic reviews.  
Methods: Umbrella review of systematic reviews of observational and interventional studies 
(randomized placebo-controlled trials, RCTs).  For each association, random-effects summary 
effect size, 95% confidence interval, and 95% prediction interval were estimated. We also assessed 
heterogeneity, evidence for small-study effect and evidence for excess significance bias. For 
significant outcomes of the RCTs, the GRADE assessment was furtherly used. 
Results: From 240 articles returned, 10 systematic reviews were included (8 of which included a 
meta-analysis), including a total of 84 studies (36 prospective observational studies and 48 
interventional). Nineteen different outcomes were included. Among observational studies, including 
a total of 1,061,637 participants, the best available evidence suggests that chocolate consumption is 
associated with reduced risk of cardiovascular disease (CVD) death (n=4 studies), acute myocardial 
infarction (n=6), stroke (n=5) and diabetes (n=6), although this was based on a weak evidence of 
credibility. Across meta-analyses of intervention studies, chocolate consumption was positively 
associated with flow-mediated dilatation at 90-150 minutes (n=3) and at 2-18 weeks (n=3), and 
insulin resistance markers (n=2). However, using the GRADE assessment, the evidence for these 
outcomes was low or very low. Data from two systematic reviews, reported that chocolate 
consumption was not associated with depressive mood or cognitive function.  
Conclusions: There is weak evidence to suggest that chocolate consumption may be associated 
with favorable health outcomes.   
 
Key words: chocolate; cardiovascular disease; umbrella review; meta-analysis.  
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INTRODUCTION 
The cocoa tree provides the basis for one of the world’s most popular food products, i.e. chocolate.  
In 2015/2016, about 7.3 million tons of retail chocolate confectionery were consumed worldwide, 
with this figure expected to reach approximately 7.7 million tons by 2018/2019 1. Whilst there is 
evidence that excessive chocolate consumption is harmful for health 2, there is some evidence that 
eaten in small-moderate amounts, chocolate may have a number of health benefits 2. Indeed, 
chocolate has been known from the ancient era as “kakawa”, meaning ‘‘Food of the Gods” possibly 
for its health benefits 3. Moreover, an ecological article reported that countries with a higher 
chocolate intake have a higher percentage of Nobel prize winners. 4 However, the findings of this 
study should be taken very cautiously due to the inherent biases of this approach.  
There is increasing research from laboratory experiments and human studies suggesting that 
chocolate consumption may be beneficial for several health outcomes, particularly cardiovascular 
health.5 Among the components present in chocolate, particular importance is given to flavonoids. 6 
Flavonoids might be protective against cardiovascular disease (CVD) through several pathways, 
including their influence as antioxidant, antiplatelet, and anti-inflammatory agents 6 Similarly, 
flavonoids in chocolate might be able to improve other potential risk factors for CVD, such as 
hypercholesterolemia, hypertension as well as improve endothelial function.7  
Furthermore, chocolate might also have beneficial effects on other diseases such as on neurological 
diseases. 2 Similarly, it is commonly thought that chocolate has important anti-depressant effects, 
possibly through its anti-inflammatory mechanism and since it promotes the production of some 
neurotransmitters, such as serotonin. 8,9  
A number of previous efforts to systematically appraise the evidence on chocolate have been 
undertaken, yet have focused on single disease endpoints, with a particular focus on CVD (some 
refs here).  However, the epidemiological credibility of this evidence for the health benefits of 
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chocolate are unclear across the totality of the evidence.  Here we used the umbrella review 
methodology (i.e. the syntheses and appraisal of existing systematic reviews) 10-12 to capture the 
breadth of outcomes associated with dietary chocolate intake. To identify health outcomes or 
medical conditions with the strongest evidence we systematically assessed the quality and strength 
of the evidence across all health outcomes or medical conditions. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
6 
 
 
 
MATERIALS AND METHODS 
Literature search and selection criteria 
An umbrella review was carried out following standardized procedures13,14. Umbrella reviews 
provide important information  that can be utilized by decision makers in healthcare to understand a 
broad topic area. 14 We systematically searched the MEDLINE/PubMed, Scopus, Embase, 
Cochrane Library / DARE databases from inception until 07th January 2018 with the following 
search strategy: “(chocolate OR cocoa) and (meta-an* or systematic review)”. Next, we searched 
reference lists of eligible articles and so on until no further papers could be identified. We included 
formal systematic review with or without meta-analyses of observational and interventional studies 
investigating chocolate and any health outcome. No language restrictions were applied.  
The primary screening (i.e., title/abstract screening) was carried out by two authors (NV, BS) and 
any disagreements were resolved  via screening of the disagreed title/abstract by a third author 
(SM). Full-texts were sourced  of all potentially eligible articles, and screened  by two investigators 
(NV, BS) who determined the final references to be included. Conference abstracts were also 
considered.  
We included: 1) peer-reviewed systematic reviews, with or without meta-analysis, that assessed 
chocolate intake using validated dietary questionnaires (e.g. food-frequency questionnaire [FFQ], 
24 h recall, 7 days questionnaire etc.); 2) meta-analyses of observational studies (case-control or 
prospective cohort studies) that investigated the association of chocolate intake at baseline with any 
incident health-related outcomes (e.g. CVD, cancer, death, diabetes etc.); 3) meta-analyses of 
randomized controlled trials (RCTs), including at least one group using placebo. Studies that 
reported effect sizes - odds ratio (OR), relative risk (RR), or hazard ratio (HR) at follow-up or mean 
difference (MD) or standardized mean differences (SMD) - for the outcomes of interest were 
analyzed through a meta-analytic approach. The others were summarized descriptively.  
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Conversely, cross-sectional and RCTs studies using only active groups (e.g. people taking different 
forms of chocolate or other dietary products) were excluded. We finally excluded meta-analyses 
based on individual data without a systematic review of the literature.  
Data extraction 
The following information were extracted from each article by two independent investigators (SC, 
JD) : (1) first author name; (2) year of publication; (3) journal; (4) type of chocolate (e.g. dark, 
milk, all types) and the categorization of chocolate intake (e.g. quintiles, quartiles, continuous); (5) 
number of included studies and participants in each meta-analysis; (6) the inclusion criteria for 
studied population; (7) effect size used in each meta-analysis; (8) study design (case-control, 
prospective, RCTs); (9) number of cases and controls in each study.  
We then extracted the study-specific estimated relative risk, adjusted for the maximum number of 
covariates available for health outcome (RR, OR, HR), along with the 95% confidence intervals 
(CI), and the number of cases for each study by chocolate intake. For meta-analyses including 
RCTs, we extracted MDs and the number of people randomized to chocolate or placebo groups. For 
observational studies, assuming a linearity for the association between chocolate intake and health 
outcomes, lowest and highest quantiles were used in the final analyses and thus this data was 
extracted. Where two meta-analyses were found for the same association the analyses with the 
largest number of studies was included. 
 
Data analysis 
For each meta-analysis, summary effect size and 95% CI were estimated using fixed and random-
effects models 15 To further consider between-study effects  prediction intervals and  corresponding 
95% CI were calculated, s, this also estimates the certainty of the association if another study 
addresses that same association. 16 The standard error (SE) of the effect size was calculated for the 
largest dataset of each meta-analysis,. If the SE was less than 0.10 then the 95% CI would be lower 
than 0.20 (which is less than the magnitude of a small effect size). To estimate between study 
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associations the I2 metric was used; high heterogeneity was indicated by values > 50% and very 
high heterogeneity >75% 17,18.  
We used the regression asymmetry test suggested by Egger and coworkers 19 to calculate evidence 
of small-study effects. A p value < 0.10 with more conservative effects in larger studies than in 
random-effects meta-analysis was considered as indicative of small-study effects. 20 
The excess significance test 21 was used to evaluate whether the number of studies with nominally 
significant results (p< 0.05) included in a meta-analysis is too great based on the power  of these 
data sets to detect effects at α=0.05. We calculated the power estimate for each data set. The sum of 
the power estimates of each study provides the expected (E) number of data sets with nominal 
statistical significance. The number of expected ‘positive’ (significant data sets) studies can be 
compared with the observed (O) number of significant studies through a χ2-based test. 21 Greater the 
difference between O and E, the greater the degree of excess of significance bias. The true effect 
size of a meta-analysis is unknown. We considered the effect size of the largest dataset (i.e., with 
the lower SE), from  this we calculated effect sizes of each constituent study  utilizing an algorithm 
that employs a non-central t distribution. Where p< 0.10 excess significance for single meta-
analysis was considered. For each meta-analysis O versus E comparison were carried out, 
separately. However, comparisons were  extended to groups including a large number of  meta-
analyses after summing the O and E values of each individual meta-analysis. 
 
Quality of the meta-analyses 
We assessed the methodological quality of the included meta-analyses using AMSTAR.22 We 
categorized the overall AMSTAR score as high (8-11 items achieved), moderate (4-7 items) and 
low (0-3 items).22 
 
Credibility assessment 
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The credibility assessment criteria employed in the present review are based on established tools 
applied to observations evidence10,13,23. Evidence from meta-analyses of observational studies with 
nominally significant summary results (p<0.05) were classified into four categories (class I, II, III, 
and IV). We considered as: 1) convincing (class I)  associations with a statistical significance of 
P<10−6, included >1,000 cases (or for continuous outcomes > 20,000 participants), had the largest 
component study reporting a significant result (P<0.05), had a 95% prediction interval excluding 
the null, large heterogeneity (I2 <50%) was not present, and no evidence of small study effects 
(P>0.10) was observed and of excess significance bias (P>0.10); 2) highly suggestive (class II) 
evidence when  associations reported a significance of P<0.001, included >1,000 cases (or for 
continuous outcomes >20,000 participants), and had the largest component study reporting a 
statistically significant result (P<0.05); 3) suggestive (class III) evidence when associations that 
reported a significance of P<0.01 with > 1,000 cases (or for continuous outcomes >20,000); 4) 
weak (class IV) evidence for significant associations with p<0.05.  
Evidence from meta-analyses of randomized controlled trials was assessed in terms of the 
significance of the summary effect (p<0.01, 0.01≤ p<0.05, p≥0.05), 95% prediction interval 
(excluding the null or not), and presence of large heterogeneity (I2 >50%), small study effects 
(P>0.10), and excess significance (P>0.10).23 When the p-value for the random effect was <0.05, 
we evaluated the evidence using the GRADE (Grading of Recommendations, Assessment, 
Development and Evaluation) assessment.24   
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
10 
 
 
 
RESULTS 
Literature review 
As shown in Figure 1, the literature review identified 240 unduplicated papers. After applying the 
inclusion or exclusion criteria, 22 full-texts were identified and of them 10 were eligible, including 
8 meta-analyses and two systematic reviews without meta-analysis.  Across the included studies 
was a total of 84 eligible original studies. 25-34 These systematic reviews and meta-analyses included 
19 health outcomes (Table 1). Ten of these outcomes were derived from meta-analyses including 
RCTs, and the other nine from observational studies, all from longitudinal cohort studies.   
 
Meta-analyses of observational studies  
As reported in Table 1, seven outcomes were included, the median number of studies included for 
each outcome was 5 (range 4-6), the median number of participants was 144,823 (57,709 to 
322,732) for a total of 1,061,637 people, and the median number of cases was 8,749 (4,553 to 
16,626), although this last information was available only for three meta-analyses. All the outcomes 
included cardiovascular diseases or cardiovascular mortality, except one which considered incident 
diabetes as the outcome (Table 1).   
Overall, 4 out of the 7 outcomes reported nominally significant summary results (p<0.05), but none 
of them survived the application of a more stringent P value (P ?< ?1 ?× ?10−6), the lowest P-value 
being 0.001.  
The study with the largest sample size for each database had a SE of less than 0.10 for all the 
outcomes (except for stroke) and a more conservative effect compared to the random-effects model 
in six outcomes. Heterogeneity among studies was present for two outcomes, diabetes and CVD 
death. Only one association (stroke) presented a 95 % prediction interval excluding the null value. 
The evidence for excess statistical significance (i.e. whether smaller studies tend to give 
substantially larger estimates of effect size compared with larger studies) was present for two 
outcomes, i.e. atrial fibrillation and heart failure.  
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Based on the above criteria, all the significant outcomes (CVD death, acute myocardial infarction, 
stroke and diabetes) have a weak level of evidence (Table 1) and for the other three outcomes 
(coronary artery disease, atrial fibrillation and heart failure), no significant association was found.  
 
The median AMSTAR score was 6 (range: 2-7), indicating a moderate quality of these meta-
analyses (Supplementary Table 1).  
 
Findings from systematic review without meta-analysis 
Two systematic reviews (without formal meta-analysis) investigating depression/depressive mood 
and cognitive disorders as outcomes were included. The results of the first systematic review 26 
indicate that consumption of chocolate had no protective effects against depression, even if these 
findings were limited only to one longitudinal study, whilst the RCTs included in this review did 
not use placebo and consequently were not eligible for our work. 26 The other systematic review 
reported no significant effect on cognitive function in one small placebo-RCT. 25  
 
Meta-analyses of randomized placebo-controlled trials  
As reported in Table 2, ten outcomes were included, the median number of studies included for 
each outcome was 4 (range 2-11), the median number of participants was 177 (median 89 
randomized to chocolate and 88 to placebo) for a total of 2,601 people. All the outcomes included 
cardiovascular or metabolic outcomes (Table 2).   
Overall, only three (flow-mediated dilatation 90-150 minutes, flow-mediated dilatation 2-18 weeks 
and insulin resistance markers) out of the 10 outcomes reported nominally significant summary 
results (p<0.05) and, of them, no one survived the application of a more stringent P value (P ?< ?1 ?×
10−6), being the lowest p-value=0.002. However, using the GRADE assessment the certainty of 
evidence for these outcomes was very low or low, mainly due to limited sample sizes included 
(Table 3).  
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The study with the largest sample size of each database reported significant results only for one 
outcome (i.e. flow mediated dilatation at 90-150 minutes). Heterogeneity among studies was absent 
(I2<50%) for all the outcomes, except two (HDL cholesterol and flow-mediated dilatation at 90-150 
minutes). No outcome presented 95 % prediction interval excluding the null value. The evidence for 
excess statistical significance (i.e. whether smaller studies tend to give substantially larger estimates 
of effect size compared with larger studies) was absent in all the outcomes included.  
 
The median AMSTAR score was 5 (range: 3-10), indicating a moderate quality of these meta-
analyses (Supplementary Table 2).  
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DISCUSSION 
In this study, including 84 original studies and a large cohort of over 1 million people that 
consumed chocolate, we found weak evidence that chocolate consumption is associated with CVD 
death, acute myocardial infarction, stroke and diabetes. We arrived at this position by evaluating the 
epidemiological credibility of the evidence, an approach which has been used in other research 
specialties 12,35, including nutritional epidemiology.36 This critical appraisal of the literature is 
necessary, since often researchers widely use a nominal significance level at p<0.05 to claim novel 
associations. However, increasing research is showing that findings based on this threshold can only 
constitute a weak evidence and there are ongoing debates on redefining the level of statistical 
significance using more stringent criteria (e.g. p<0.0001).37 For example, in our umbrella review, 
seven (four observational and three interventional) outcomes were statistically significant (as 
p<0.05), but no convincing or highly suggestive evidence was evident for any of the outcomes 
included.    
In observational studies, we found a weak evidence that chocolate could be beneficial for the 
prevention of CVD and for diabetes. Altogether, these findings suggest that, even if these outcomes 
are significant, they are affected by some limitations and or biases that globally discourage the use 
of chocolate for the prevention of these medical conditions. We can try to explain these findings 
through some hypotheses. First, the kinds of chocolate included were heterogeneous, whilst it is 
reported that dark chocolate might give its consumers health benefits, the milk variety cannot 38 
probably for an higher presence of flavonoids and anti-oxidant components. Unfortunately, the 
studies included in our syntheses did not differentiate between the consumption of dark and milk 
chocolate. Second, chocolate is rich added sugars and added sugar consumption seems to be 
associated with an increased risk for CVD.39 Moreover, as shown by a large study in European 
people, persons eating more frequently chocolate had more frequently an unhealthier diet, e.g. they 
eat less frequently vegetables and fruits and introduce less amounts of fibers.40 Even if the analyses 
were adjusted for all these confounders, it is also possible that the beneficial effect of chocolate 
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were counterbalanced by these unhealthy habits. Second, three of the four statistically significant 
outcomes were affected by publication bias, suggesting that more original work with significant 
results were published than one would normally expect41 Finally, the populations included at 
baseline in these observational studies were heterogeneous, since they included healthy participants 
or at high risk of a developing a condition (e.g. overweight for diabetes).   
We were able to find two systematic reviews regarding the possible role of chocolate on two health 
outcomes, i.e. depression and cognitive dysfunction, suggesting that chocolate consumption has no 
impact on these outcomes. However, these findings were unfortunately limited to one longitudinal 
study (for depression) and to one small RCT (for cognitive outcomes). Therefore, other studies are 
needed to clarify these associations. 
Finally, the findings of the meta-analyses of the RCTs included confirmed the results of 
observational studies. Of the ten outcomes (all regarding cardiovascular and metabolic health), only 
three were statistically significant at a p-value<0.05. Using the GRADE assessment for these 
significant outcomes, the certainty of the evidence was low or very low, mainly due to the limited 
sample sizes used in these RCTs. The effect of chocolate on cardiometabolic health is attributed to 
arterial dilatation, a mechanism supported by clinical and animal research. It was hypothesized that 
NOX-2, the catalytic subunit of NADPH oxidase, has a key role in the formation of reactive oxidant 
species and is involved in impairment of flow-mediated dilation.42 Chocolate (particularly dark) 
exerts artery dilatation via down-regulating NOX2-mediated oxidative stress, and it seems to 
improve walking ability in patients affected by peripheral artery disease.43 Moreover, the regulation 
of nitric oxide (NO) production by the flavonoids present in dark chocolate could explain its effects 
on insulin resistance.44 However, the findings of RCTs were small in sample size (median n = 177), 
and they also used different kinds of chocolate products and usually had a short follow-up period (in 
median 8 weeks). Moreover, many of the RCTs included in the original meta-analyses were not 
eligible, since they frequently used as control other kinds of chocolate, e.g. dark vs. milk chocolate. 
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Therefore, we need future interventional trials in order to better understand the role of chocolate in 
improving these health outcomes.  
 
Whilst this large umbrella review provides important novel insights, a number of limitations should 
be considered.  A credibility assessment criteria was used that was based on  established tools for 
observational evidence. 23 Even if none of the components of these criteria provides definitive proof 
of lack of reliability, they cumulatively include the possibility that the results are susceptible to bias 
and uncertainty. Meta-analyses contained  studies that differed in their design, population and other  
characteristics. To account for this, we used an I2<50% as one of the criteria for class I evidence 
(convincing) in order to assign the best evidence grade only to robust associations and without any 
suspect of bias. Second, meta-analyses have  limitations 45 and results likely depend on decisions 
relating to which estimates  are selected from each primary study and how to apply them in the 
meta-analysis (e.g. in the present  review a number of meta-analyses failed to  report information on 
types/kinds of chocolate  or combined active and placebo groups in the RCTs). This may be a 
relevant issue when the factor of interest is continuous, and when different comparisons of levels of 
the risk factor may be selected to express risk 46. Finally, the meta-analyses of RCTs, as mentioned 
above, included studies with a low quality, mainly due to a limited sample size. In this regard, we 
believe that our umbrella review using more stringent criteria for assessing the credibility of the 
evidence and including systematic reviews that consider many treatment comparisons for the 
management of the same disease or condition13 could better approach the issue if chocolate is 
beneficial or not for health outcomes. Moreover, except for the meta-analyses cited in our work, the 
other works available for this topic are mainly narrative reviews, consequently limiting the 
generalization of these findings in daily clinical practice.  
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CONCLUSIONS 
Our umbrella review of the top tier of evidence from systematic reviews and meta-analyses suggests 
that there are minimal or weak evidence for chocolate consumption on health outcomes such as 
diabetes and cardiovascular conditions. Therefore, our results did not support routinely use of 
chocolate for improving or preventing cardiovascular and metabolic diseases. However, we 
encourage future studies (both observational and interventional) to confirm/refuse our findings.  
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FIGURE LEGEND 
Figure 1. PRISMA flow-chart 
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Table 1. Health outcomes and evidence class reported in included meta-analyses of observational studies.  
Outcome 
(reference) Population 
Level of  
comparison 
N of  
studies 
N of 
participants 
N of 
cases 
Risk ratio 
(95% CI) 
p-
value 
95% CI  
predictio
n  
intervals 
I2 Publication bias 
P-value 
for 
excess 
significa
nce test 
Small 
study 
effect  
Largest 
study 
significa
nt 
Evidence 
class1 
CVD death 
28
 
Healthy 
Highest vs.  
lowest 
category and 
continuous 
4 57,709 NA 0.650 (0.465-0.909) 0.01 
0.15- 
2.74 82.6 Yes NA Yes Yes IV 
AMI 
27
 
Healthy 
and  
general 
population 
Highest vs.  
lowest 
category 
6 144,823 8,749 0.895 (0.822-0.975) 0.01 
0.74- 
1.08 24.3 Yes No No Yes IV 
Stroke 
32
 
General  
population 
Highest vs.  
lowest 
category 
5 322,732 NA 0.858 (0.786-0.937) 0.001 
0.74- 
0.99 0 No NA No No IV 
Diabetes 
32
 
General 
population 
Highest vs.  
lowest 
category 
6 146,385 NA 0.842 (0.725-0.978) 0.02 
0.56- 
1.26 54.2 Yes NA Yes No IV 
Coronary 
artery 
Disease 
32
 
General 
population 
Highest vs.  
lowest 
category 
4 104,514 NA 0.885 (0.775-1.010) 0.07 
0.55- 
1.42 47.3 No NA No Yes NS 
Atrial 
fibrillation 
31
 
General  
population 
Highest vs.  
lowest 
category 
6 180,534 16,626 0.963 (0.898-1.032) 0.284 
0.87- 
1.06 0 No Yes No No NS 
Heart  
Failure 
30
 
General  
population 
Highest vs.  
lowest 
category 
4 104,940 4,553 0.908 (0.815-1.013) 0.08 
0.72- 
1.15 0 No Yes No No NS 
Summary 
statistics   
Median
=5 
Median= 
144,823 
Median
=8,749          
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Outcome 
(reference) Population 
Level of  
comparison 
N of  
studies 
N of 
participants 
N of 
cases 
Risk ratio 
(95% CI) 
p-
value 
95% CI  
predictio
n  
intervals 
I2 Publication bias 
P-value 
for 
excess 
significa
nce test 
Small 
study 
effect  
Largest 
study 
significa
nt 
Evidence 
class1 
(range: 
4-6) 
(range: 
57,709 to 
322,732) 
(range: 
4,553 to 
16,626) 
 
Abbreviations: AMI: acute myocardial infarction; CVD: cardiovascular disease; CI: confidence intervals; NA: not available.  
1Evidence class criteria: class I (convincing): statistical significance with P<10−6, more than 1,000 cases (or >20,000 participants for continuous 
outcomes), the largest component study reported statistically significant effect (P<0.05); 95% prediction interval excluded the null; no large 
heterogeneity (I2 <50%), no evidence of small study effects (P>0.10) and excess significance bias (P>0.10); class II (highly suggestive): statistical 
significance with P<10−6, more than 1,000 cases (or >20,000 participants for continuous outcomes), the largest component study reported 
statistically significant effect (P<0.05); class III (suggestive): statistical significance with P<10−3, more than 1,000 cases (or >20,000 participants for 
continuous outcomes); class IV (weak): the remaining statistically significant associations with P<0.05. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 2. Health outcomes and evidence class reported in included meta-analyses of randomized placebo-controlled studies.  
Outcome 
(reference) 
N of 
studies 
N of 
participants 
(treated; 
placebo) 
Mean difference 
(95% CI) 
p-
value 
95% CI 
prediction 
intervals 
I2 Publication bias 
P-value for 
excess 
significance 
test 
Small 
study 
effect 
Largest 
study 
significant 
Flow mediated dilatation 
(90-150 min) 
26
 
3 134 (67; 67) 
4.452 
(1.605-7.299) 0.002 
-27.99; 
36.89 76.1 No No No Yes 
Flow mediated dilatation 
(2-18 weeks) 
26
 
3 87 (43; 44) 
2.111 
(0.735-3.488) 0.003 
-6.81; 
11.03 0 
No No No No 
Insulin resistance 
Markers 
26
 
2 49 (24; 25) 
-0.461 
(-0.899 to -0.023) 0.039 NA 0 
No NA NA No 
Fasting 
Insulin 
26
 
3 88 (44; 44) 
-1.940 
(-4.863 to 0.983) 0.193 
-26.15; 
22.27 20.3 
No No No No 
Fasting 
plasma glucose 
26
 
4 127 (63; 64) 
-0.07 
(-0.282; 0.143) 0.522 
-0.54; 
0.40 0 
No No No No 
LDL 
Cholesterol 
25
 
4 220 (111; 109) 
-3.063 
(-11.00; 4.875) 0.450 
-20.49; 
14.36 0 
No No No No 
HDL 
Cholesterol 
25
 
4 220 (111; 109) 
-1.328 
(-7.262; 4.605) 0.661 
-25.45; 
22.80 61.3 
No No No No 
Triglycerides 
25
 
4 220 (111; 109) 
-10.09 
(-25.50; 5.32) 0.199 
-43.92; 
23.73 0 
No NA NA No 
Systolic 
blood pressure 
29
 
18 728 (365; 363) 
-0.93 
(-2.635; 0.769) 0.285 
-6.86; 
4.99 64.5 
No No No No 
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Outcome 
(reference) 
N of 
studies 
N of 
participants 
(treated; 
placebo) 
Mean difference 
(95% CI) 
p-
value 
95% CI 
prediction 
intervals 
I2 Publication bias 
P-value for 
excess 
significance 
test 
Small 
study 
effect 
Largest 
study 
significant 
Diastolic 
blood pressure 
29
 
18 728 (365; 363) 
-1.117 
(-2.592; 0.237) 0.103 
-6.37; 
4.02 69.8 
No No No No 
Summary statistics Median=4 (range: 2-18) 
Median=177 
(89; 88)     
 
   
 
Abbreviations: CI: confidence intervals; NA: not available; NS: not significant. 
Evidence class criteria: class I (convincing): statistical significance with P<0.01; 95% prediction interval excluded the null; no large heterogeneity 
(I2 <50%), no evidence of small study effects (P>0.10) and excess significance bias (P>0.10); class II (highly suggestive): statistical significance 
with 0.01<p<0.05; class III: no significant association (p>0.05).  
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Table 3. GRADE assessment of the significant outcomes in meta-analyses of randomized controlled trials 
 
№ of participants 
(studies) 
Risk of bias Inconsistency Indirectness Imprecision Publication bias Overall certainty 
of evidence 
Flow mediated dilatation (90-150 minutes) 
134 
(3 RCTs)  
not serious  very serious a not serious  serious b none  ⨁◯◯◯ 
VERY LOW  
Flow mediated dilatation (2-18 weeks) 
87 
(3 RCTs)  
not serious  not serious  not serious c very serious c none  ⨁⨁◯◯ 
LOW  
Insulin resistance markers 
49 
(2 RCTs)  
not serious  not serious  not serious  very serious c none  ⨁⨁◯◯ 
LOW  
 
Abbreviations: CI: Confidence interval. Explanations: a. I2 >=75% ; b. Less than 200 participants; c. Less than 100 participants.  
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database searching in PubMed, 
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Additional records identified 
through manual search 
(n = 0) 
Records after duplicates were removed 
(n = 234) 
Records screened 
(n = 234) 
Records excluded based on 
title/abstract 
(n = 212) 
Full-text articles 
assessed for eligibility  
(n = 22) 
Publications excluded (n = 12) 
Doubled (n=10) 
Protocol (n=1) 
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